Kymera Therapeutics Inc is a biotechnology company focused on developing innovative therapeutics that harness the power of targeted protein degradation to treat a range of diseases, including cancer and autoimmune disorders

By utilizing its proprietary technology platform, the company aims to design and create small molecules that can selectively degrade specific proteins, thereby offering a novel approach to addressing previously difficult-to-target biological pathways. Kymera's pipeline includes a variety of drug candidates that advance the understanding of protein function and the potential for transformative treatments, positioning the company at the forefront of the next generation of precision medicine.